FOR GENEVAX: FROM GENES TO TRANSNATIONAL VACCINES (Q2035463): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Removed claims)
(‎Changed an Item: The budget was changed)
Property / budget
 
308,305.94 Euro
Amount308,305.94 Euro
UnitEuro
Property / budget: 308,305.94 Euro / rank
 
Normal rank
Property / EU contribution
 
136,610.15 Euro
Amount136,610.15 Euro
UnitEuro
Property / EU contribution: 136,610.15 Euro / rank
 
Normal rank
Property / co-financing rate
 
44.31 percent
Amount44.31 percent
Unitpercent
Property / co-financing rate: 44.31 percent / rank
 
Normal rank

Revision as of 09:06, 12 February 2022

Project Q2035463 in Italy
Language Label Description Also known as
English
FOR GENEVAX: FROM GENES TO TRANSNATIONAL VACCINES
Project Q2035463 in Italy

    Statements

    country
    Italy
    0 references
    EU contribution
    136,610.15 Euro
    0 references
    budget
    308,305.94 Euro
    0 references
    co-financing rate
    44.31 percent
    0 references
    start time
    14 February 2017
    0 references
    expected end time
    13 October 2019
    0 references
    beneficiary name (string)
    EVVIVAX S.R.L.
    0 references
    ISTITUTO SUPERIORE DI SANITA'
    0 references
    beneficiary
    Q282303
    0 references
    Q275708
    0 references
    programme
    Lazio - ERDF
    0 references
    coordinate location

    41°53'35.95"N, 12°28'58.55"E
    0 references
    summary
    I VACCINI GENETICI HANNO MOLTEPLICI VANTAGGI POTENZIALI, TRA CUI IL TARGETING SPECIFICO, L'USO DI GENI MULTIPLI PER MIGLIORARE L'IMMUNITà, LA VELOCITà DI SINTESI E LA RIDUZIONE DEL RISCHIO RISPETTO AI VACCINI CONVENZIONALI. EVVIVAX Ê UNA NUOVA AZIENDA CH (Italian)
    0 references
    GENETIC VACCINES HAVE MULTIPLE POTENTIAL BENEFITS, INCLUDING SPECIFIC TARGETING, THE USE OF MULTIPLE GENES TO IMPROVE IMMUNOLOGY, THE SPEED OF SUMMARIES AND THE REDUCTION OF RISK IN RELATION TO CONVENTIONAL VACCINES. EVVIVAX Ê A NEW COMPANY CH (English)
    0 references
    LES VACCINS GÉNÉTIQUES PRÉSENTENT DE MULTIPLES AVANTAGES POTENTIELS, Y COMPRIS UN CIBLAGE SPÉCIFIQUE, L’UTILISATION DE GÈNES MULTIPLES POUR AMÉLIORER L’IMMUNITÉ, LA VITESSE DE SYNTHÈSE ET LA RÉDUCTION DES RISQUES PAR RAPPORT AUX VACCINS CONVENTIONNELS. EVVIVAX Ê UNE NOUVELLE ENTREPRISE QUI (French)
    point in time
    16 December 2021
    0 references
    GENETISCHE VACCINS HEBBEN MEERDERE POTENTIËLE VOORDELEN, WAARONDER SPECIFIEKE TARGETING, HET GEBRUIK VAN MEERDERE GENEN OM DE IMMUNITEIT, DE SYNTHESESNELHEID EN DE RISICOVERMINDERING TE VERBETEREN IN VERGELIJKING MET CONVENTIONELE VACCINS. EVVIVAX Ê EEN NIEUW BEDRIJF DAT (Dutch)
    point in time
    23 December 2021
    0 references
    GENETISCHE IMPFSTOFFE HABEN IM VERGLEICH ZU HERKÖMMLICHEN IMPFSTOFFEN MEHRERE POTENZIELLE VORTEILE, EINSCHLIESSLICH GEZIELTER TARGETING, DER VERWENDUNG MEHRERER GENE ZUR VERBESSERUNG DER IMMUNITÄT, DER SYNTHESEGESCHWINDIGKEIT UND DER RISIKOREDUKTION. EVVIVAX Ê EIN NEUES UNTERNEHMEN, DAS (German)
    point in time
    24 December 2021
    0 references
    LAS VACUNAS GENÉTICAS TIENEN MÚLTIPLES BENEFICIOS POTENCIALES, INCLUYENDO LA ORIENTACIÓN ESPECÍFICA, EL USO DE MÚLTIPLES GENES PARA MEJORAR LA INMUNIDAD, LA VELOCIDAD DE SÍNTESIS Y LA REDUCCIÓN DEL RIESGO EN COMPARACIÓN CON LAS VACUNAS CONVENCIONALES. EVVIVAX Ê UNA NUEVA EMPRESA QUE (Spanish)
    point in time
    25 January 2022
    0 references
    location (string)
    ROMA
    0 references

    Identifiers

    Italian Unique Project Code
    F89J18000160007
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q2035463&oldid=27872600"